Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=210 Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Type 1 Diabetes Mellitus
Primary: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following…
Phase 3 N=802 SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
Endometriosis
Primary: Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52 — 84.8; 82.2; 75.6 percentage of participants
Phase 3 N=142 Randomized Open Investigation Determining Steroid Dose
Covid19
Primary: All Cause Mortality at 28 Days — 15; 12 Participants
Phase 3 N=68 Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
Spasticity in Participants With Multiple Sclerosis
Primary: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) — -0.23; -0.26 units on a scale — p=0.7152
Phase 3 N=185 Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Multiple Sclerosis · Relapsing Multiple Sclerosis · Advancing Multiple Sclerosis
Primary: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) Related to Study Drug During the Treatment Period — 59 Participants
Phase 3 N=120 Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age…
Phase 3 N=458 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Vitiligo
Primary: Time to Relapse (Defined as <F-VASI75) — NA; NA days — p=0.0414
Phase 3 N=1,605 Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
Urinary Tract Infections
Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…
Phase 3 N=193 Individualized Obesity Pharmacotherapy
Obesity
Primary: Change in Total Body Weight — -7.7; -6.5 percent change
Phase 3 N=22 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
Dupuytren's Disease
Primary: Health-related Quality of Life (HRQL) Using the Michigan Hand Outcomes Questionnaire (MHQ) — 78.1; 68.3 units on a scale — p=0.05
Phase 3 N=424 MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
Lateral Canthal Lines · Glabellar Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND…
Phase 3 N=202 Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia
Hypercholesterolemia
Primary: The Percentage Change From Baseline in LDL-C Level at Week 12. — -42.89; -37.43 Percent change from baseline
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 3 N=549 Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Arthritis, Rheumatoid
Primary: Percentage of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo — 44.8; 50.7; 57.5…